Iovance Biotherapeutics Inc. Common Stock vs Medline Inc. Class A Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.42 (market cap $5.85B), while Medline Inc. Class A Common Stock trades at $35.75 (market cap $31.10B). The key difference: Medline Inc. Class A Common Stock is far larger — about 5.3× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Medline Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Medline Inc. Class A Common Stock for 0 Days on average.
| IOVA | MDLN | |
|---|---|---|
Market Cap | $5.85B | $31.10B |
Volume | 14,517,176 | 4,471,639 |
Sector | Health | Health |
52-Week High | $14.82 | $49.99 |
52-Week Low | $1.81 | $31.64 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.78B | $41.07B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →Medline provides medical-surgical products and supply-chain solutions for healthcare providers. Its portfolio and distribution network serve hospitals, clinics, long-term care facilities, and other care settings.
Read more on MDLN →